Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset
Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.
Pharma & Biotech
Features & Analysis
Is direct-to-patient pharma becoming the industry’s answer to drug pricing pressure?
Bristol Myers Squibb and Pfizer have brought Eliquis, the oral anticoagulant apixaban, into a new direct access channel through Mark Cuban Cost Plus Drug Company, making the medicine available to cash-paying patients in the United States from April 27, 2026. The move places one of the country’s most widely prescribed branded blood thinners inside a
Pharma & Biotech
Can Bristol Myers Squibb and Pfizer protect Eliquis growth as drug pricing pressure rises?
Eliquis faces pricing pressure, but Bristol Myers Squibb and Pfizer are moving first. Direct access may become pharma’s new defence.
Medical Devices & Diagnostics
What Viz.ai’s latest hypertrophic cardiomyopathy studies reveal about the future of cardiac AI
Viz.ai’s new HCM studies suggest AI-ECG could improve detection and follow-up. Read what this changes for cardiology workflows and adoption.
Pharma & Biotech
Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
Pharma & Biotech
How Bristol Myers Squibb’s Opdivo approvals in frontline and relapsed classical Hodgkin lymphoma reset treatment pathways
Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.
Pharma & Biotech
Bristol Myers Squibb expands Sotyktu label. Will TYK2 inhibition challenge biologics in psoriatic arthritis?
FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis. Discover what TYK2 inhibition means for autoimmune treatment and future rheumatology drugs.
Medical Devices & Diagnostics
What Bristol Myers Squibb’s luspatercept results reveal about the future of alpha thalassemia care
Bristol Myers Squibb reports positive luspatercept data in alpha thalassemia. Find out what this could change for treatment and regulation.
Pharma & Biotech
Bristol Myers Squibb pushes CELMoD frontier as FDA accepts iberdomide NDA in relapsed multiple myeloma
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.
Pharma & Biotech
NMPA clears Zai Lab’s COBENFY, rewriting the schizophrenia treatment playbook
Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.